Calyxt increased the number of shares it intends to float, but slashed its offering price in half from the middle of a previously disclosed range.
The company, a division of BGI Group, sold 40.1 million shares at RMB 13.64 per share for a total of RMB 547 million ($80.6 million) in the offering.
The firm began offering its common shares on Wednesday at $6 per share on the Nasdaq. Gross proceeds from the IPO were $7.1 million.
The molecular diagnostics firm said in an amended prospectus that it plans to offer 1.3 million shares of its common stock at between $6.35 and $6.75 per share.
Samsung Biologics debuted last week in Seoul with the largest IPO in South Korea in years, according to the Associated Press.
The IPO amount is about half of what the company's competitors, Editas Medicine and Intellia Therapeutics, raised in their own IPOs earlier this year.
In a filing with the US Securities and Exchange Commission, the company said it intends to sell up to $90 million in common stock on the Nasdaq.
The molecular diagnostic company plans to avoid the IPO process but go public in China through a reverse merger with an auto parts maker.
A billionaire entrepreneur is taking his highly valued firm NantHealth public.
The company did not specify the number of shares it will offer or the offering price, but said it intends to trade on the Nasdaq Global Market.
A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.
A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.
NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.
In Nature this week: epigenetic factors that prevent healthy aging and more.